VRTX241018P480000
- 1.89
- -2.29-54.78%
Vertex Pharmaceuticals Newsroom
Scotiabank Initiates Coverage On Vertex Pharmaceuticals With Sector Perform Rating, Announces Price Target of $480
Vertex Pharmaceuticals Analyst Ratings
Vertex Pharmaceuticals Is Maintained at Buy by B of A Securities
Vertex Pharmaceuticals Analyst Ratings
BofA Securities Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Cuts Target Price to $541
Morgan Stanley Adjusts Price Target on Vertex Pharmaceuticals to $473 From $474
Vertex Pharmaceuticals (VRTX) Receives a Hold From Morgan Stanley
Raymond James Maintains Vertex Pharmaceuticals(VRTX.US) With Hold Rating
Vertex Pharmaceuticals Analyst Ratings
Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital
Analysts Offer Insights on Healthcare Companies: Teladoc (TDOC), Brookdale Senior Living (BKD) and Vertex Pharmaceuticals (VRTX)
Vertex Pharmaceuticals Analyst Ratings
Cantor Fitzgerald Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Raises Target Price to $480
Leerink Partners Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $600
DBS Maintains Vertex Pharmaceuticals(VRTX.US) With Hold Rating
Buy Rating Affirmed for Vertex Pharmaceuticals on Promising Pain Management Drug Prospects
Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital
RBC Capital Maintains Sector Perform on Vertex Pharmaceuticals, Lowers Price Target to $425
Vertex Pharmaceuticals Analyst Ratings
Analysts Conflicted on These Healthcare Names: TransMedics Group (TMDX), Vertex Pharmaceuticals (VRTX) and Edwards Lifesciences (EW)